Ipsen company profile
Company profile
Ipsen has 5,535 employees and is headquartered in Paris, France.
Ipsen is best known for Somatuline, Dysport and Decapeptyl, with Cabometyx, Onivyde, Bylvay, Iqirvo and Sohonos also among its marketed or developed medicines. The biopharmaceutical group develops and commercializes treatments in oncology, rare disease and neuroscience, selling them in North America, Europe and other international markets. Its pipeline includes candidates in Phase III trials for follicular lymphoma and pediatric low-grade gliomas, as well as earlier-stage programs in solid tumors and aesthetic indications.
In the fiscal year ended December 2025, Ipsen reported revenue of EUR 3.9 billion, up 9.9% from the previous year, and net income of EUR 443.5 million. The company employed 5,535 people and is headquartered in Paris, France, where it was founded in 1929.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- France
- Headquarters
- 70 rue Balard, 75015, Paris
- Employees
- 5,535
- Chief executive
- David Loew
- Founded
- 1929
- Fiscal year
- January - December
- Listing
- IPN · Euronext Paris
- Currency
- EUR
- ISIN
- FR0010259150
- Website
- ipsen.com
Ipsen and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| IpsenIPN | France | $14.2B | 5,535 | 27.4% | 25.5 |
| Swedish Orphan BiovitrumSOBI | Sweden | $16.27B | 2,207 | 30.9% | 25.0 |
| H. LundbeckHLUN.A | Denmark | $8.49B | 5,000 | 24.4% | 14.2 |
| HaleonHLN | United Kingdom | $40.15B | 24,535 | 23.5% | 19.3 |
| Sandoz GroupSDZ | Switzerland | $43.57B | 20,000 | 9.3% | 72.3 |
| Laboratorios Farmaceuticos RoviROVI | Spain | $3.93B | 1,950 | 20.2% | 17.4 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
